Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2022-11-16 00:00:00 ET · period of report 2022-11-14 · accession 0001209191-22-057398 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-16 | 2022-11-14 | ACRV | Holm-Jorgensen Rasmus | CFO | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
| D | 2022-11-16 | 2022-11-14 | ACRV | Holm-Jorgensen Rasmus | CFO | A - Grant | $0.00 | +60.1K | 60.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-14 | A | A | 20,030 | $0.00 | 20,030 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-11-14 | A | A | 60,090 | $0.00 | 60,090 | D | $12.50 · — to 2032-11-13 | 60,090 Common Stock | (F2) Twenty-five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the grant date, and the remaining shares subject to the option shall vest in 36 equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |